Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study

被引：2
作者：
Autore, Francesco [1 ]
Visentin, Andrea [2 ]
Deodato, Marina [3 ]
Vitale, Candida [4 ,5 ]
Galli, Eugenio [1 ]
Fresa, Alberto [1 ]
Fazzi, Rita [6 ]
Sanna, Alessandro [7 ]
Olivieri, Jacopo [8 ]
Scortechini, Ilaria [9 ]
Del Principe, Maria Ilaria [10 ]
Sportoletti, Paolo [11 ]
Schiattone, Luana [12 ]
Maschio, Nilla [13 ]
Facchinelli, Davide [14 ]
Marchesi, Francesco [15 ]
Coscia, Marta [4 ,5 ]
Tedeschi, Alessandra [3 ]
Trentin, Livio [2 ]
Innocenti, Idanna [1 ]
Candoni, Anna [8 ,16 ]
Busca, Alessandro [4 ,5 ]
Pagano, Livio [1 ]
Laurenti, Luca [1 ]
机构：
[1] Fdn Policlin Univ A Gemelli IRCCS, Largo Agostino Gemelli 8, I-00168 Rome, Italy
[2] Univ Padua, Padua, Italy
[3] ASST Grande Osped Metropolitano Niguarda, Milan, Italy
[4] Univ Torino, AOU Citta Salute & Sci Torino, Turin, Italy
[5] Univ Torino, Dipartimento Biotecnol Mol & Sci Salute, Turin, Italy
[6] Azienda Osped Univ Pisana, Pisa, Italy
[7] Azienda Osped Univ Careggi, Florence, Italy
[8] Clin Ematol Udine, Udine, Italy
[9] Azienda Osped Univ Marche, Ancona, Italy
[10] Univ Roma Tor Vergata, Dipartimento Biomed & Prevenz, Rome, Italy
[11] AO Santa Maria Misericordia Perugia, Perugia, Italy
[12] Presidio Osped S Spirito Pescara, Pescara, Italy
[13] Oncoematol Ist Oncol Veneto IOV IRCCS, Padua, Italy
[14] Osped San Bortolo, Vicenza, Italy
[15] IRCCS Regina Elena Natl Canc Inst, Rome, Italy
[16] Univ Modena & Reggio Emilia, Modena, Italy
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2024年 / 99卷 / 05期
关键词：
RITUXIMAB;
D O I：
10.1002/ajh.27247
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：982 / 984
页数：3
相关论文
共 39 条
  • [1] Venetoclax for the treatment of patients with chronic lymphocytic leukemia
    Crombie, Jennifer
    Davids, Matthew S.
    FUTURE ONCOLOGY, 2017, 13 (14) : 1223 - 1232
  • [2] A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia
    Hampel, Paul J.
    Swaminathan, Mahesh
    Rogers, Kerry A.
    Parry, Erin M.
    Burger, Jan A.
    Davids, Matthew S.
    Ding, Wei
    Ferrajoli, Alessandra
    Hyak, Jonathan M.
    Jain, Nitin
    Kenderian, Saad S.
    Wang, Yucai
    Wierda, William G.
    Woyach, Jennifer A.
    Parikh, Sameer A.
    Thompson, Philip A.
    BLOOD ADVANCES, 2024, 8 (10) : 2342 - 2350
  • [3] Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia
    Samuels, Courtney
    Abbott, Diana
    Niemiec, Sierra
    Tobin, Jennifer
    Falco, Angela
    Halsema, Keri
    Kamdar, Manali
    CANCER REPORTS, 2022, 5 (05)
  • [4] The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia
    Vitale, Candida
    Ferrajoli, Alessandra
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (08) : 885 - 894
  • [5] Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia
    Huber, Henriette
    Edenhofer, Simone
    von Tresckow, Julia
    Robrecht, Sandra
    Zhang, Can
    Tausch, Eugen
    Schneider, Christof
    Bloehdorn, Johannes
    Fuerstenau, Moritz
    Dreger, Peter
    Ritgen, Matthias
    Illmer, Thomas
    Illert, Anna L.
    Duerig, Jan
    Boettcher, Sebastian
    Niemann, Carsten U.
    Kneba, Michael
    Fink, Anna-Maria
    Fischer, Kirsten
    Doehner, Hartmut
    Hallek, Michael
    Eichhorst, Barbara
    Stilgenbauer, Stephan
    BLOOD, 2022, 139 (09) : 1318 - 1329
  • [6] Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia
    Fischer, Kirsten
    Al-Sawaf, Othman
    Hallek, Michael
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2020, (01) : 357 - 362
  • [7] Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia
    Allan, John N.
    Flinn, Ian W.
    Siddiqi, Tanya
    Ghia, Paolo
    Tam, Constantine S.
    Kipps, Thomas J.
    Barr, Paul M.
    Camburn, Anna Elinder
    Tedeschi, Alessandra
    Badoux, Xavier C.
    Jacobs, Ryan
    Kuss, Bryone J.
    Trentin, Livio
    Zhou, Cathy
    Szoke, Anita
    Abbazio, Christopher
    Wierda, William G.
    CLINICAL CANCER RESEARCH, 2023, 29 (14) : 2593 - 2601
  • [8] Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed or Refractory Chronic Lymphocytic Leukemia
    Rogers, Kerry A.
    Huang, Ying
    Ruppert, Amy S.
    Abruzzo, Lynne V.
    Andersen, Barbara L.
    Awan, Farrukh T.
    Bhat, Seema A.
    Dean, Allison
    Lucas, Margaret
    Banks, Christin
    Grantier, Cara
    Heerema, Nyla A.
    Lozanski, Gerard
    Maddocks, Kami J.
    Valentine, Thomas R.
    Weiss, David M.
    Jones, Jeffrey A.
    Woyach, Jennifer A.
    Byrd, John C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (31) : 3626 - +
  • [9] Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma
    Izutsu, Koji
    Yamamoto, Kazuhito
    Kato, Koji
    Ishikawa, Takayuki
    Fukuhara, Noriko
    Terui, Yasuhito
    Choi, Ilseung
    Humphrey, Kathryn
    Kim, Su Young
    Okubo, Sumiko
    Ogawa, Natsumi
    Nishimura, Yasuko
    Salem, Ahmed Hamed
    Maruyama, Dai
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (03) : 370 - 380
  • [10] Early Treatment of High-Risk Chronic Lymphocytic Leukemia With Alemtuzumab and Rituximab
    Zent, Clive S.
    Call, Timothy G.
    Shanafelt, Tait D.
    Tschumper, Renee C.
    Jelinek, Diane F.
    Bowen, Deborah A.
    Secreto, Charla R.
    LaPlant, Betsy R.
    Kabat, Brian F.
    Kay, Neil E.
    CANCER, 2008, 113 (08) : 2110 - 2118
1234